Antares Pharma (ATRS) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 3 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
For this week, the average consensus of the company shares are rated as a Strong Buy. Antares Pharma (NASDAQ:ATRS): The stock opened at $1.14 on Thursday but the bulls could not build on the opening and the stock topped out at $1.16 for the day. The stock traded down to $1.05 during the day, due to lack of any buying support eventually closed down at $1.07 with a loss of -6.14% for the day. The stock had closed at $1.14 on the previous day. The total traded volume was 469,550 shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the officer (SVP General Counsel, Secretary) of Antares Pharma, Inc., Graham Peter J had purchased shares worth of $15,400 in a transaction dated on March 21, 2016. A total of 20,000 shares were purchased at a price of $0.77 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.